1-2 of 2
Niranjan Rao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Clinical Trials & Observations
Keith W. Pratz, Jorge Cortes, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small, Judith E. Karp, Mark Levis
Journal: Blood
Blood (2009) 113 (17): 3938–3946.
https://doi.org/10.1182/blood-2008-09-177030
Published: 2009
Journal Articles

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

Jorge Cortes, MD, Gail J. Roboz, MD, Hagop Kantarjian, MD, Eric Feldman, MD, Judy Karp, MD, Allyson Pollack, Katrina Sandy, RN, Niranjan Rao, Shiro Akinaga, Mark Levis, MD
Journal: Blood
Blood (2007) 110 (11): 909.
https://doi.org/10.1182/blood.V110.11.909.909
Published: 2007